Clinical Trials
16
Active:4
Completed:5
Trial Phases
5 Phases
Phase 1:1
Phase 2:3
Phase 3:3
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 4
7 (43.8%)Phase 2
3 (18.8%)Phase 3
3 (18.8%)Not Applicable
2 (12.5%)Phase 1
1 (6.3%)Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate
Phase 3
Recruiting
- Conditions
- Rheumatoid ArthritisJAK InhibitorBiomarkerMusculoskeletal Ultrasound
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Atsushi Kawakami
- Target Recruit Count
- 155
- Registration Number
- NCT05121298
- Locations
- 🇯🇵
Nagasaki University Hospital, Nagasaki, Japan
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Phase 3
- Conditions
- Musculoskeletal UltrasoundBiomarkerRheumatoid ArthritisIL-6 InhibitorJAK Inhibitor
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Atsushi Kawakami
- Target Recruit Count
- 400
- Registration Number
- NCT05090410
- Locations
- 🇯🇵
Nagasaki University Hospital, Nagasaki, Japan
News
No news found